A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma
Sponsor: TORL Biotherapeutics, LLC
Sponsor score: 0
ClinicalTrials ID:NCT07439653
This Phase 1/2 trial assesses TORL-5-700's safety and efficacy in relapsed/refractory NHL. Eligible participants must have confirmed B-NHL, ECOG ≤ 2, measurable lesions, available tumor tissue, and adequate organ function. The study involves monotherapy dose escalation, expansion at MTD/RP2D, and combination therapy, with dosing every three weeks.
Patient Parameters
| Parameter | Options |
|---|
Program Overview
A Phase 1/2 study to evaluate safety, tolerability, and anticancer activity of TORL-5-700 as a monotherapy and in combination in R/R NHL
Eligibility Criteria
Inclusion Criteria
- Confirmed B-NHL, including but not limited to de novo DLBCL; FL, Grades 1 to 3A; MCL; transformed lymphoma (tFL, RT) and FL Grade 3B; MZL and MALT.
- Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2.
- At least 1 measurable lesion per Lugano criteria.
- Tumor tissue is available.
- Adequate organ function
Exclusion Criteria
- T-cell lymphoma
- CLL or SL
- Burkitt lymphoma and high-grade B-cell lymphoma
- CNS involvement
- Peripheral neuropathy > Grade 2
- Uncontrolled medical conditions
- Viral infections
Locations
| FACILITY | ZIP | CITY | STATE |
|---|---|---|---|
| UCLA | 90404 | Santa Monica | California |
| Stanford University | 94305 | Stanford | California |
| Sarah Cannon Research Institute | 37203 | Nashville | Tennessee |
Get This Program In Your Inbox
You can sign up and apply your patients for this program.